CompletedPhase 3

A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients

South Korea356 participantsStarted 2024-05-10

Plain-language summary

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension

Who can participate

Age range

19 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Subjects whose clinic blood pressure measured in visit 1 corresponds to the following conditions
. Subjects whose clinic and ambulatory blood pressure measured in visit 2 corresponds to the following conditions

Exclusion criteria

. Difference between arms greater than 20 mmHg for mean sitSBP or 10mmHg for mean sitDBP at Visit 1
. Patients who have taken more than three components of Blood pressure medication within 3 months prior to Visit 1
. Orthostatic hypotension with symptoms within 3 months prior to visit 1
. Secondary hypertension patient or suspected to be
. Uncontrolled type II diabetes mellitus (HbA1c \> 9%) or type I diabetes mellitus
. Severe heart disease or severe neurovascular disease
. Moderate or malignant retinopathy
. Severe renal diseases (eGFR\<30mL/min/1.73m2)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change from baseline in 24 hours ambulatory systolic blood pressure

Timeframe: baseline, 10 weeks

Trial details

NCT IDNCT06174766

SponsorHanmi Pharmaceutical Company Limited

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-01-08

View on ClinicalTrials.gov More Hypertension trials